EFFECT OF TAMOXIFEN ON SERUM-CHOLESTEROL AND LIPOPROTEINS DURING CHEMOHORMONAL THERAPY
EFFECT OF TAMOXIFEN ON SERUM-CHOLESTEROL AND LIPOPROTEINS DURING CHEMOHORMONAL THERAPY
复制标题
DOI：
10.1016/0009-8981(93)90061-8
复制
发表时间：
1993-12-31
影响因子：
5
通讯作者：
SCHWARTZ, DC
中科院分区：
文献类型：
--
作者：
DNISTRIAN, AM;SCHWARTZ, MK;SCHWARTZ, DC
研究了三苯氧胺对晚期乳腺癌患者血清胆固醇、高密度脂蛋白胆固醇（HDL-胆固醇）、低密度脂蛋白胆固醇（LDL-胆固醇）及LDL-胆固醇/HDL-胆固醇比值（LDL-C/HDL-C）的影响。对24例接受他莫昔芬（10 mg，每日两次）治疗的患者进行的纵向研究表明，血清总胆固醇（17%）和LDL胆固醇（27%）平均降低，而他莫昔芬对HDL胆固醇的影响因患者而异。LDL-C/HDL-C比值显著降低（33%），与冠状动脉疾病风险降低一致。无论他莫昔芬单独给药还是与细胞毒性化疗联合给药，他莫昔芬对与心血管疾病相关的风险因素的有益影响在绝经前和绝经后患者中都很明显。
The effect of tamoxifen on serum cholesterol, high density lipoprotein cholesterol (HDL-cholesterol), low density lipoprotein cholesterol (LDL-cholesterol) and the ratio of LDL-cholesterol to HDL-cholesterol (LDL-C/HDL-C) was investigated in breast cancer patients undergoing therapy for advanced disease. Longitudinal studies in 24 patients treated with tamoxifen (10 mg, twice daily) indicated average decreases in total serum cholesterol (17%) and LDL-cholesterol (27%), whereas the effect of tamoxifen on HDL-cholesterol varied with the individual patient. There was a significant decrease in the LDL-C/HDL-C ratio (33%) consistent with a decreased risk for coronary artery disease. This beneficial influence of tamoxifen on risk factors associated with cardiovascular disease was evident in both premenopausal and postmenopausal patients whether tamoxifen was administered alone or in combination with cytotoxic chemotherapy.